Bardoxolone Methyl

For research use only.

Catalog No.S8078 Synonyms: RTA 402, TP-155, NSC 713200, CDDO Methyl Ester, CDDO-Me

17 publications

Bardoxolone Methyl Chemical Structure

CAS No. 218600-53-4

Bardoxolone Methyl (RTA 402, TP-155, NSC 713200, CDDO Methyl Ester, CDDO-Me) is an IKK inhibitor, showing potent proapoptotic and anti-inflammatory activities; Also a potent Nrf2 activator and nuclear factor-κB (NF-κB) inhibitor. Bardoxolone Methyl abrogates ferroptosis. Bardoxolone methyl induces apoptosis and autophagy in cancer cells.

Selleck's Bardoxolone Methyl has been cited by 17 publications

3 Customer Reviews

  • Renal Nrf2 activity was shown in RTA402-treated acFSGS (RTA402 + acFSGS) mice as early as day 7 (RTA402 + acFSGS) and persisted to day 28, compared to vehicle + acFSGS mice. Kidney in situ ROS production demonstrated by DHE detection.

    Free Radic Biol Med, 2014, 73:260-9 . Bardoxolone Methyl purchased from Selleck.

  • KG-1a cells were treated with Bar (0.5 µM) or a vehicle for 48 h and Annexin V/PI staining was detected after 48 h by flow cytometry.

    Oncol Rep, 2017, 38(3):1517-1524. Bardoxolone Methyl purchased from Selleck.

  • Cells were exposed to increasing concentrations of Bardoxolone methyl (BM; 0–1000 nM) and AR protein levels were measured. Top panels show representative immunoblots depicting AR-FL, AR-V7 and GAPDH levels. Bottom panels show fold change in AR proteins, normalized to GAPDH levels.

    Oncol Rep, 2017, 38(5):2774-2786. Bardoxolone Methyl purchased from Selleck.

Purity & Quality Control

Choose Selective IκB/IKK Inhibitors

Biological Activity

Description Bardoxolone Methyl (RTA 402, TP-155, NSC 713200, CDDO Methyl Ester, CDDO-Me) is an IKK inhibitor, showing potent proapoptotic and anti-inflammatory activities; Also a potent Nrf2 activator and nuclear factor-κB (NF-κB) inhibitor. Bardoxolone Methyl abrogates ferroptosis. Bardoxolone methyl induces apoptosis and autophagy in cancer cells.
Features The only IKKβ inhibitor in clinical use for solid tumors, type 2 diabetes, and chronic kidney disease. An orally-available antioxidant inflammation modulator.
Targets
IKK [3]
(Cell-free assay)
Ferroptosis [7]
()
Nrf2 [6]
()
NF-κB [6]
()
In vitro

Bardoxolone Methyl exhibits potent inhibitory activities against production of nitric oxide induced by interferon-Ƴ in mouse macrophages with IC50 of 0.1 nM. [1] Bardoxolone Methyl decreases the viability of leukemic HL-60, KG-1, and NB4 cells with IC50 of 0.4, 0.4, and 0.27 μM, respectively. CDDO-Me induces pro-apoptotic Bax protein, inhibits the activation of ERK1/2, and it blocks Bcl-2 phosphorylation, which contributes to the induction of apoptosis. [2] Bardoxolone Methyl potently inhibits both constitutive and inducible NF-kappaB activated by TNF, interleukin (IL)-1beta, phorbol ester, okadaic acid, hydrogen peroxide, lipopolysaccharide, and cigarette smoke. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 MoLuSpVv[3Srb36gZZN{[Xl? Mnf3TY5pcWKrdH;yfUBkd26lZX70doF1cW:wIHHnZYlve3RicILvcIln\XKjdHnvckBw\iCPQ1[tO{ApTVJiUH;zbZRqfmVrIHLy[YF{fCClYX7j[ZIh[2WubIOsJGlEPTB;MD6wOe69VQ>? MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTN4OUO5Okc,OTV|NkmzPVY9N2F-
BMDM M{DWNGN6fG:2b4jpZ4l1gSCjc4PhfS=> MkfINlQhcHK| NV[0enFDS3m2b4TvfIlkcXS7IHHnZYlve3RiQ{W3RmwwPiCvb4Xz[UBDVUSPIHPlcIx{KGG|c3Xzd4VlKGG|IFzETEBz\WynYYPlJIFnfGW{IEK0JIhzeyxiTV7USF0xNjYQvF2= MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV|M{e5NEc,OjJ3M{O3PVA9N2F-
BMDM MW\BcpRqcW6obHHtcYF1d3K7IHHzd4F6 NVH1Z3JlOC53IIXN MmD3NUBpeg>? MoXpRY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDpckBEPTeETD:2JI1wfXOnIFLNSG0h[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDMVHMue3SrbYXsZZRm\CCWTl\hcJBp[SCycn;keYN1cW:wIHH0JFAvPSC3TTDwdoV1emWjdHXkJIZweiBzIHjyJIJm\m:{ZTDMVHMh[2ijbHzlcodmKGGodHXyJFghfG9iMkSgbJJ{KGK7IHntcZVvd2G|c3H5 NUftWXVMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1N|M4QTBpPkKyOVM{PzlyPD;hQi=>
PANC1343 M17Te2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 NH[5S5Y{ODBidH:gNVAxOCCwTR?= NVHvXFFCPzJiaILz MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKFCDTlOxN|Q{KGOnbHzzJIF1KDNyMDD0c{AyODByIH7NJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYm= NH;XcII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO4PFgxPid-MkSzPFg5ODZ:L3G+
RAW264.7 NFqxWIFCdnSrb4jp[IFvfCCjc4PhfS=> M1PkOVExOCCwTR?= M2qwUFE5KGi{cx?= NWTmeJR2SW62aX;4bYRidnRiYXP0bZZqfHliaX6gcY92e2ViUlHXNlY1NjdiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB1SkiSLXnu[JVk\WRiUl;TJJBzd2S3Y4Tpc44h[XRiMUCwJI5OKHC{ZYTy[YF1\WRiZn;yJFE5KGi{czDi[YZwemViY3jhcIxmdmenIH3lZZN2emWmIHHmeIVzKDF3IH3pcpMh[nliSELER2ZCNWKjc3XkJIZtd3diY4n0c41mfHK7 NG\1[Yo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO4PFgxPid-MkSzPFg5ODZ:L3G+
HepG2 M13VcWN6fG:2b4jpZ4l1gSCjc4PhfS=> MkHrOFghcHK| MX\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUSuPVnPxE1? NWnZT5lrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PFU2PDVpPkK0Olg2PTR3PD;hQi=>
B16F10 M3;pOWN6fG:2b4jpZ4l1gSCjc4PhfS=> NYDUXJZsPDhiaILz M1rEZ2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGIyPkZzMDDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVUvQDYQvF2= NVj4ZoJIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PFU2PDVpPkK0Olg2PTR3PD;hQi=>
CCD-841-CoN MorsRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M1HE[FczKGi{cx?= NG\2[2RCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPDSE05PDFvQ3;OJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5|MUdOwG0> NG\ufIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[3OVE1PCd-MkW2O|UyPDR:L3G+
HCT8 NV\UW5BUSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M3;HSlczKGi{cx?= MYHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IEWtSnUhemW|aYP0ZY51KGi3bXHuJGhEXDhiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlM3O87:TR?= MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ5NUG0OEc,OjV4N{WxOFQ9N2F-
HCT8 NULYSIxjSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NVTobmdSPzJiaILz MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEigZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjN7Od88US=> MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ5NUG0OEc,OjV4N{WxOFQ9N2F-
HCT8 NHT4flNHfW6ldHnvckBie3OjeR?= MmH2NUB2VQ>? NEXGXIEzPCCqcoO= NWn0OmtXUW6qaXLpeIlwdiCxZjDITWYuOWGucHjhJJBzd3SnaX6g[ZhxemW|c3nvckBqdiCqdX3hckBJS1R6IHPlcIx{KGG2IEGgeW0hcW6ldXLheIVlKG[xcjCyOEBpenNiYomgW4V{fGW{bjDicI91fGmwZzDt[ZRpd2R? NGO0cYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[3OVE1PCd-MkW2O|UyPDR:L3G+
HCT8 MlT6SpVv[3Srb36gZZN{[Xl? MkDFNUB2VQ>? MkK4NlQhcHK| Ml3wTY5pcWKrdHnvckBw\iCKSV[tNYFteGijIIDyc5RmcW5iZYjwdoV{e2mxbjDpckBHXS2{ZYPpd5RidnRiaIXtZY4hUEOWODDj[YxteyCjdDCxJJVOKGmwY4XiZZRm\CCob4KgNlQhcHK|IHL5JHdme3Sncn6gZoxwfHSrbnegcYV1cG:m NVr0NnhPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2O|UyPDRpPkK1Olc2OTR2PD;hQi=>
HCT8 NGi5d4lHfW6ldHnvckBie3OjeR?= NEX3Z4MyKHWP NX\aPJhUOjRiaILz M4HwXGlvcGmkaYTpc44hd2ZiU2TBWFMheHKxdHXpckBxcG:|cHjvdplt[XSrb36gbY4hcHWvYX6gTGNVQCClZXzsd{BifCBzIIXNJIlv[3WkYYTl[EBnd3JiMkSgbJJ{KGK7IGfld5Rmem5iYnzveJRqdmdibXX0bI9l MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ5NUG0OEc,OjV4N{WxOFQ9N2F-
HCT8 NW\hR|NETnWwY4Tpc44h[XO|YYm= NXnLXY1uOSC3TR?= MmrRNlQhcHK| NUeyVWxoUW6qaXLpeIlwdiCxZjDTWGFVOyCycn;0[YlvKHCqb4PwbI9zgWyjdHnvckBqdiCIVT3y[ZNqe3SjboSgbJVu[W5iSFPUPEBk\WyuczDheEAyKHWPIHnuZ5Vj[XSnZDDmc5IhOjRiaILzJIJ6KFenc4Tldo4h[myxdITpcochdWW2aH;k NV7FdZhRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2O|UyPDRpPkK1Olc2OTR2PD;hQi=>
HCT8 MVTGeY5kfGmxbjDhd5NigQ>? NW\UXZVjOSC3TR?= NGHLPJEzPCCqcoO= NYj0PXRlUW6qaXLpeIlwdiCxZjDBT3QheHKxdHXpckBxcG:|cHjvdplt[XSrb36gbY4hcHWvYX6gTGNVQCClZXzsd{BifCBzIIXNJIlv[3WkYYTl[EBnd3JiMkSgbJJ{KGK7IGfld5Rmem5iYnzveJRqdmdibXX0bI9l MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ5NUG0OEc,OjV4N{WxOFQ9N2F-
HCT8 NH3tfXVHfW6ldHnvckBie3OjeR?= MlriNUB2VQ>? MVGyOEBpenN? NF;ZbGhKdmirYnn0bY9vKG:oIFHLWEBxem:2ZXnuJJBpd3OyaH;yfYxifGmxbjDpckBHXS2{ZYPpd5RidnRiaIXtZY4hUEOWODDj[YxteyCjdDCxJJVOKGmwY4XiZZRm\CCob4KgNlQhcHK|IHL5JHdme3Sncn6gZoxwfHSrbnegcYV1cG:m MmDhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4N{WxOFQoRjJ3Nke1NVQ1RC:jPh?=
HCT8 MXTGeY5kfGmxbjDhd5NigQ>? MYGxJJVO NX;GXWx{OjRiaILz NIexc2tKdmirYnn0bY9vKG:oIFXST{Bxem:2ZXnuJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDIR3Q5KGOnbHzzJIF1KDFidV2gbY5kfWKjdHXkJIZweiB{NDDodpMh[nliV3XzeIVzdiCkbH;0eIlv\yCvZYToc4Q> M3;xNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nke1NVQ1Lz5{NU[3OVE1PDxxYU6=
HCT8 M{C5fGZ2dmO2aX;uJIF{e2G7 MYKxJJVO MVGyOEBpenN? M4\GOGlvcGmkaYTpc44hd2ZiRWLLJJBzd3SnaX6gdIhwe3Cqb4L5cIF1cW:wIHnuJGZWNXKnc3nzeIFvfCCqdX3hckBJS1R6IHPlcIx{KGG2IEGgeW0hcW6ldXLheIVlKG[xcjCyOEBpenNiYomgW4V{fGW{bjDicI91fGmwZzDt[ZRpd2R? NF:zfG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[3OVE1PCd-MkW2O|UyPDR:L3G+
HCT8 MUHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MUCxJJVO MYC3NkBpenN? MorjRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ2S4JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIHH0JFEhfU1iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigQ>? NYLMSYg4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2O|UyPDRpPkK1Olc2OTR2PD;hQi=>
HCT8 MUXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NXzsdW1COSC3TR?= MWW3NkBpenN? NEi4cnJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JFUuTlVicnXzbZN1[W62IHj1cYFvKEiFVEigZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iYYSgNUB2VSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6 M{XvSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nke1NVQ1Lz5{NU[3OVE1PDxxYU6=
BEAS2B NHrKcWJHfW6ldHnvckBie3OjeR?= MljVNVAhfU1? MY[2JIhzew>? M1nsUGFkfGm4YYTpc44hd2ZiToLmNkBqdiCqdX3hckBDTUGVMlKgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hUE9zIHflcoUh\XiycnXzd4lwdiCjdDCxNEB2VSCrbnP1ZoF1\WRiZn;yJFYhcHK|IHL5JJFRS1JibXX0bI9l MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ5OECyPEc,OjZ{N{iwNlg9N2F-
H42E NGLIVFRHfW6ldHnvckBie3OjeR?= M3;FPFI1KGi{cx?= MkDOTY5lfWO2aX;uJI9nKE6URkKgZYN1cX[jdHnvckBqdiC{YYSgTFQzTSClZXzsd{BmgHC{ZYPzbY5oKEGURUjMJIF{e2W|c3XkJIF{KHKncH;yeIVzKHS{YX7z[4Vv\SCjY4Tpeol1gSCjZoTldkAzPCCqcoOgZpkhdHWvaX7ld4NmdmOnIHHzd4F6NCCFRE2wMlAxODYQvF2= NHvxSVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkmwPFE4Oyd-Mk[5NFgyPzN:L3G+
H42E M3\oSWN6fG:2b4jpZ4l1gSCjc4PhfS=> M4j4WlI1KGi{cx?= MXLDfZRwfG:6aXPpeJkh[WejaX7zeEBz[XRiSESySUBk\WyuczDlfJBz\XO|aX7nJGFTTTiOIHHzd4V{e2WmIHHzJINmdGy3bHHyJGFVWCCuZY\lcEBi\nSncjCyOEBpenNiYomgR4VtdHSrdHXyMWdtdyCudX3pcoV{[2WwdDDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlTPxE1? MmPpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7MEixO|MoRjJ4OUC4NVc{RC:jPh?=
H42E M4TBb2Z2dmO2aX;uJIF{e2G7 M1z3PVAvODFidH:gN|Ahdk1? MUSxJIhz NHT1WoRUfGGkaXzpfoF1cW:wIH;mJG5TTjJiaX6gdoF1KEh2MlWgZ4VtdHNiZYjwdoV{e2mwZzDBVmU5VCCjdDCwMlAyKHSxIEOwJI5OKGGodHXyJFEhcHJiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ NIPTelU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkmwPFE4Oyd-Mk[5NFgyPzN:L3G+
NHBE MUPDfZRweHKxdHXjeIl3\SCjc4PhfS=> MVywMlAxOSC2bzCwMlEhfU1? M3vOUFE5KGi{cx?= NEXpcVREgXSxcILveIVkfGm4ZTDhZ5Rqfmm2eTDpckBPUEKHIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhfEKKUD3pcoR2[2WmIFfTTEBl\XCuZYTpc44h[XRiMD6wNFEhfG9iMD6xJJVOKHC{ZXnuZ5Vj[XSnZDDmc5IhOThiaILzJIZwdGyxd3XkJIJ6KHSESGCgZYRlcXSrb36g[o9zKDRiaILzJIJ6KHSqaX;zeIFzKGS7ZTDiZZNm\CCobIXvdoV{[2WwY3WgZZN{[Xl? NWL2bFM{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewN|E3PzBpPkK3NFMyPjdyPD;hQi=>
NHBE MkjCSpVv[3Srb36gZZN{[Xl? NVqwZZZnOTByIH7N NFjiNI4zPCCqcoO= M1Syb2lvcGmkaYTpc44hd2ZiS1XBVFEwVlKIMjDpcpRmemGldHnvckBqdiCQSFLFJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKEeFTF2gcXJPSSCneIDy[ZN{cW:wIHH0JFExOCCwTTDpcoN2[mG2ZXSg[o9zKDJ2IHjyd{BqdiCycnXz[Y5k\SCxZjDuc44hfGG{Z3X0bY5oKHOrUl7BJIJ6KHGUVD3QR3IhdWW2aH;k MnzWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyM{G2O|AoRjJ5MEOxOlcxRC:jPh?=
NHBE NGfyZ4xHfW6ldHnvckBie3OjeR?= NI\yZ40yODBibl2= NX;6T25KOjRiaILz MUDJcohq[mm2aX;uJI9nKEuHQWCxM25TTjJiaX70[ZJi[3Srb36gbY4hVkiERTDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBPWU9zIH3SUmEh\XiycnXzd4lwdiCjdDCxNFAhdk1iaX7jeYJifGWmIH\vdkAzPCCqcoOgbY4heHKnc3XuZ4Uhd2Zibn;uJJRiemendHnu[{B{cVKQQTDifUByWlRvUFPSJI1mfGixZB?= Mo\NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyM{G2O|AoRjJ5MEOxOlcxRC:jPh?=
NHBE M4jnNmZ2dmO2aX;uJIF{e2G7 M2DZWFExOCCwTR?= NEnqT2E1QCCqcoO= M3fVUmlvcGmkaYTpc44hd2ZiS1XBVFEwVlKIMjDpcpRmemGldHnvckBqdiCQSFLFJINmdGy|IHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCQUV:xJJNx\WOrZnnjJIFkfGm4aYT5JIF1KDFyMDDuUUBqdmO3YnH0[YQh\m:{IES4JIhzeyCrbjDwdoV{\W6lZTDv[kBvd25idHHy[4V1cW6pIIPpVm5CKGK7IF3UWEBz\WS3Y4Tpc44h[XO|YYm= NXvjUVZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewN|E3PzBpPkK3NFMyPjdyPD;hQi=>
HaCaT-ARE-luc MXTGeY5kfGmxbjDhd5NigQ>? M4H0dFYhcHK| Ml7wRYN1cX[jdHnvckBw\iCQcn[yJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKGi3bXHuJGhiS2GWLVHSSU1tfWNiY3XscJMh[W[2ZYKgOkBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwQVAvODcQvF2= NELWc4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEe1N|I6PCd-Mki3OVMzQTR:L3G+
NIH/3T3 MWjGeY5kfGmxbjDhd5NigQ>? Ml\TOkBpenN? M3G5NWlvcGmkaYTpc44hd2ZiVF7GMYFteGijIIP0bY12dGG2ZXSgUmYuc2GycHHCJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKG2xdYPlJG5KUC9|VEOgZ4VtdHNiYX\0[ZIhPiCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR|UxRTFwMt88US=> MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDd3M{K5OEc,Ojh5NUOyPVQ9N2F-
HeLa M1HB[GZ2dmO2aX;uJIF{e2G7 MVe2JIhzew>? MlftTY5pcWKrdHnvckBw\iCLRl6t[4FudWFic4TpcZVt[XSnZDDTWGFVOyBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDoeY1idiCKZVzhJINmdGy|IHHmeIVzKDZiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygTWM2OD1{LkO4{txO NXTEcI9GRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3OVMzQTRpPkK4O|U{Ojl2PD;hQi=>
RAW264.7 NFmydIFCdnSrLXnu[oxidW2jdH;yfUBie3OjeR?= NUKwTHQ2SW62aT3pcoZt[W2vYYTvdpkh[WO2aY\peJkhcW5ibX;1d4UhWkGZMk[0Mlch[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDubZRzcWNib4jp[IUheHKxZIXjeIlwdixiSVO1NF01|ryP NETKRog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEe1OFQ4OCd-Mki3OVQ1PzB:L3G+
HEK293 NV;5NJV1S3m2b4TvfIlkcXS7IHHzd4F6 NFTFSokzPCCqcoO= MVrDfZRwfG:6aXPpeJkh[WejaX7zeEBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;Mj6y{txO NHTNfVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm5OFI5Pid-Mki5PVQzQDZ:L3G+
H9c2 M4j6ZmN6fG:2b4jpZ4l1gSCjc4PhfS=> NEL5eoczPCCqcoO= NWGxWnVWS3m2b4TvfIlkcXS7IHHnZYlve3RicnH0JGg6[zJiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDJ2IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PS5{zszN M{LvVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUm0Nlg3Lz5{OEm5OFI5PjxxYU6=
HEK293 NXTUWppJTnWwY4Tpc44h[XO|YYm= NYLpT|RGOjByIITvJFExODBibl2= MXOyOEBpenN? NVjxbnpvUW6qaXLpeIlwdiCxZjDJT2tj\XSjIDj1cotvd3ewIH;ybYdqdilidILhcpNn\WO2ZXSgbY4hUEWNMkmzJINmdGy|IHHzd4V{e2WmIHHzJHRPTmGucHjhMYlv\HWlZXSgUmZs[XCyYVKgZYN1cX[jdHnvckBifCB{MECgeI8hOTByMDDuUUBi\G2rbnnzeIVz\WRiNjDodpMh[W[2ZYKgWG5H[WyyaHGgd5RqdXWuYYTpc44hdWWjc4Xy[YQh\m:{IEK0JIhzeyCkeTDOSotieHCjQj3kdol3\W5ibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5 M2PrTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUm0Nlg3Lz5{OEm5OFI5PjxxYU6=
HEK293 NVzrT|BZTnWwY4Tpc44h[XO|YYm= M1zP[lIxOCC2bzCxNFAxKG6P NIHyW2szPCCqcoO= M3G5bmlvcGmkaYTpc44hd2ZiSVvLZoV1[SBqdX7rco94diCxcnnnbY4qKHS{YX7z[oVkfGWmIHnuJGhGUzJ7MzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hXE6IYXzwbIEucW6mdXPl[EB2eHKnZ4XsZZRqd25ib3[gbW5QWyCvUl7BJIV5eHKnc4Ppc44h[XRiMkCwJJRwKDFyMECgcm0h[WSvaX7pd5RmemWmIE[gbJJ{KGGodHXyJHRPTmGucHjhJJN1cW23bHH0bY9vKG2nYYP1doVlKG[xcjCyOEBpenNiYomgdZVidnSrdHH0bZZmKFKWLWDDVkBidg>? M3XxelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUm0Nlg3Lz5{OEm5OFI5PjxxYU6=
HEK293 MXvGeY5kfGmxbjDhd5NigQ>? NGX6c2UzODBidH:gNVAxOCCwTR?= NGOwdHQzPCCqcoO= MnXiTY5pcWKrdHnvckBw\iCLS1vi[ZRiKCi3bnvuc5dvKG:{aXfpckkhfHKjboPm[YN1\WRiaX6gTGVMOjl|IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBVVk[jbIDoZU1qdmS3Y3XkJJVxemWpdXzheIlwdiCxZjDDU3gzKG2UTlGg[ZhxemW|c3nvckBifCB{MECgeI8hOTByMDDuUUBi\G2rbnnzeIVz\WRiNjDodpMh[W[2ZYKgWG5H[WyyaHGgd5RqdXWuYYTpc44hdWWjc4Xy[YQh\m:{IEK0JIhzeyCkeTDxeYFvfGm2YYTpeoUhWlRvUFPSJIFv M1i3XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUm0Nlg3Lz5{OEm5OFI5PjxxYU6=
HEK293 MXXGeY5kfGmxbjDhd5NigQ>? MX6yNFAhfG9iMUCwNEBvVQ>? NUPEfYNsOjRiaILz MUfJcohq[mm2aX;uJI9nKEmNS3LleIEhMHWwa37ve44hd3KrZ3nuLUB1emGwc3\lZ5Rm\CCrbjDISWszQTNiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJHRPTmGucHjhMYlv\HWlZXSgeZBz\We3bHH0bY9vKG:oIF3DVFEhdVKQQTDlfJBz\XO|aX;uJIF1KDJyMDD0c{AyODByIH7NJIFldWmwaYP0[ZJm\CB4IHjyd{Bi\nSncjDUUmZidHCqYTDzeIlufWyjdHnvckBu\WG|dYLl[EBnd3JiMkSgbJJ{KGK7IIH1ZY51cXSjdHn2[UBTXC2SQ2KgZY4> M2GzbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUm0Nlg3Lz5{OEm5OFI5PjxxYU6=
intraglomerular mesangial cells M3j1eGZ2dmO2aX;uJIF{e2G7 M1PUO|AvPjVibXevb4c> M1;aWlEzKHenZXvz MVnS[Y5weHKxdHXjeIl3\SCjY4Tpeol1gSCrbjDkZk9l[iCvb4Xz[UBie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDueY1j\XJib3[gbY51emGpbH;t[ZJ2dGG{IH3ld4Fv\2mjbDDj[YxteyCjdDCwMlY2KG2pL3vnMEBqeCCjZH3pcol{fGW{ZXSgeJJq[2VicHXyJJdm\WtiZn;yJFEzKGOxboPlZ5V1cX[nIIfl[Yt{KG2nYYP1doVlKGG2IEGxJJdm\Wu|IIDvd5Qh\G:|ZTDifUBJN0Vvc4ThbY5qdmdiYnHz[YQhdWmlcn;zZ49xcWNiYX7hcJl{cXN? NEnvbIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm5OFI5Pid-Mki5PVQzQDZ:L3G+
HEK293 MX\GeY5kfGmxbjDhd5NigQ>? MoL1NlAxKHSxIEGwNFAhdk1? MUmyOEBpenN? Ml;NTY5pcWKrdHnvckBw\iCLS1vi[ZRiKCi3bnvuc5dvKG:{aXfpckkhfHKjboPm[YN1\WRiaX6gTGVMOjl|IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBVVk[jbIDoZU1qdmS3Y3XkJJVxemWpdXzheIlwdiCxZjDDU3gzKHC{b4TlbY4h\XiycnXzd4lwdiCjdDCyNFAhfG9iMUCwNEBvVSCjZH3pcol{fGW{ZXSgOkBpenNiYX\0[ZIhXE6IYXzwbIEhe3SrbYXsZZRqd25ibXXhd5Vz\WRiZn;yJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RibXX0bI9l NWLzc5pXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5PVQzQDZpPkK4PVk1Ojh4PD;hQi=>
HEK293 NI\hXVZHfW6ldHnvckBie3OjeR?= MlXkNlAxKHSxIEGwNFAhdk1? MoLTNlQhcHK| NVSwcohkUW6qaXLpeIlwdiCxZjDJT2tj\XSjIDj1cotvd3ewIH;ybYdqdilidILhcpNn\WO2ZXSgbY4hUEWNMkmzJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCWTl\hcJBp[S2rbnT1Z4VlKHWycnXneYxifGmxbjDv[kBqVk:VIIDyc5RmcW5iZYjwdoV{e2mxbjDheEAzODBidH:gNVAxOCCwTTDh[I1qdmm|dHXy[YQhPiCqcoOgZYZ1\XJiVF7GZYxxcGFic4TpcZVt[XSrb36gcYVie3W{ZXSg[o9zKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4SgcYV1cG:m M4TsZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUm0Nlg3Lz5{OEm5OFI5PjxxYU6=
HEK293 MoH0SpVv[3Srb36gZZN{[Xl? M1f6WlIxOCC2bzCxNFAxKG6P NWr3VW14OjRiaILz NE\LRmdKdmirYnn0bY9vKG:oIFnLT4JmfGFiKIXub45wf25ib4Lp[4lvMSC2cnHud4Zm[3SnZDDpckBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOgcYl1cWejdHnvckBw\iCWTl\hcJBp[S2rbnT1Z4VlKGmwY4LlZZNmKGmwIILheIlwKG:oIH71Z4xm[XJidH:gZ5l1d3OxbHnjJJA3PSCjdDCyNFAhfG9iMUCwNEBvVSCjZH3pcol{fGW{ZXSgOkBpenNiYX\0[ZIhXE6IYXzwbIEhe3SrbYXsZZRqd25ibXXhd5Vz\WRiZn;yJFI1KGi{czDifUBY\XO2ZYLuJIJtd3R? NVzFNWNsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5PVQzQDZpPkK4PVk1Ojh4PD;hQi=>
HEK293 NF2wNGxHfW6ldHnvckBie3OjeR?= NH;UO|czODBidH:gNVAxOCCwTR?= NGnsWlIzPCCqcoO= NGjUToFKdmirYnn0bY9vKG:oIFnLT4JmfGFiKIXub45wf25ib4Lp[4lvMSC2cnHud4Zm[3SnZDDpckBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKFSQRnHsdIhiNWmwZIXj[YQhfXC{ZXf1cIF1cW:wIH;mJG1EWDFicILveIVqdiCneIDy[ZN{cW:wIHH0JFIxOCC2bzCxNFAxKG6PIHHkcYlvcXO2ZYLl[EA3KGi{czDh[pRmeiCWTl\hcJBp[SC|dHnteYxifGmxbjDt[YF{fXKnZDDmc5IhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDt[ZRpd2R? MoO5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7OUSyPFYoRjJ6OUm0Nlg3RC:jPh?=
HEK293 M3LMVWZ2dmO2aX;uJIF{e2G7 MkXMNlAxKHSxIEGwNFAhdk1? MlPqOFghcHK| NFO3N|VKdmirYnn0bY9vKG:oIFvlZZAyN06{ZkKgLJVvc26xd36gc5Jq\2mwKTDpcpRmemGldHnvckB1emGwc3\lZ5Rm\CCrbjDISWszQTNiY3XscJMh[XO|ZYPz[YQh[XNidYDy[Yd2dGG2aX;uJI9nKEiRLUGgcXJPSSCneIDy[ZN{cW:wIHH0JFIxOCC2bzCxNFAxKG6PIHHmeIVzKDR6IHjyd{BjgSCzdXHueIl1[XSrdnWgVnQuWEOUIHHuZYx6e2m| NU\wfHV6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5PVQzQDZpPkK4PVk1Ojh4PD;hQi=>
HEK293 NHHu[2lHfW6ldHnvckBie3OjeR?= M{juRVIxOCC2bzCxNFAxKG6P MXO0PEBpenN? Mm\ETY5pcWKrdHnvckBw\iCNZXHwNU9PemZ{IDj1cotvd3ewIH;ybYdqdiliaX70[ZJi[3Srb36geJJidnOoZXP0[YQhcW5iSFXLNlk{KGOnbHzzJIF{e2W|c3XkJIF{KHWycnXneYxifGmxbjDv[kBPWU9zIH3SUmEh\XiycnXzd4lwdiCjdDCyNFAhfG9iMUCwNEBvVSCjZoTldkA1QCCqcoOgZpkheXWjboTpeIF1cX[nIGLUMXBEWiCjbnHsfZNqew>? NHu4TXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm5OFI5Pid-Mki5PVQzQDZ:L3G+
HEK293 MXzGeY5kfGmxbjDhd5NigQ>? MYiyNFAhfG9iMUCwNEBvVQ>? MYK0PEBpenN? NGW0RpRKdmirYnn0bY9vKG:oIFvlZZAyN06{ZkKgLJVvc26xd36gc5Jq\2mwKTDpcpRmemGldHnvckB1emGwc3\lZ5Rm\CCrbjDISWszQTNiY3XscJMh[XO|ZYPz[YQh[XNiYXP0bZZifGmxbjDv[kBPemZ{IHH0JFIxOCC2bzCxNFAxKG6PIHHmeIVzKDR6IHjyd{BjgSCDUlWt[JJqfmWwIHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfS=> NEfq[4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm5OFI5Pid-Mki5PVQzQDZ:L3G+
HEK293 NWHrcGVrTnWwY4Tpc44h[XO|YYm= M3nCXFIxOCC2bzCxNFAxKG6P M2\WUFQ5KGi{cx?= NFnue2VKdmirYnn0bY9vKG:oIFvlZZAyN06{ZkKgLJVvc26xd36gc5Jq\2mwKTDpcpRmemGldHnvckB1emGwc3\lZ5Rm\CCrbjDISWszQTNiY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gcpVkdGWjcjD0c{BkgXSxc3;sbYMhVm[{MjDyZZRqdyCjdDCyNFAhfG9iMUCwNEBvVSCjZoTldkA1QCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl7NEK4Okc,Ojh7OUSyPFY9N2F-
HEK293 MkXnSpVv[3Srb36gZZN{[Xl? M2qweFIxOCC2bzCxNFAxKG6P NVr2[FZ4PDhiaILz MojMTY5pcWKrdHnvckBw\iCNZXHwNU9PemZ{IDj1cotvd3ewIH;ybYdqdiliaX70[ZJi[3Srb36geJJidnOoZXP0[YQhcW5iSFXLNlk{KGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHP5eI9{d2yrYzDIU{0yKGyndnXsd{BifCB{MECgeI8hOTByMDDuUUBi\nSncjC0PEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ M4qwd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUm0Nlg3Lz5{OEm5OFI5PjxxYU6=
HEK293 NFqwSW5HfW6ldHnvckBie3OjeR?= M4fSRVIxOCC2bzCxNFAxKG6P MXm0PEBpenN? Mn;yTY5pcWKrdHnvckBw\iCNZXHwNU9PemZ{IDj1cotvd3ewIH;ybYdqdiliaX70[ZJi[3Srb36geJJidnOoZXP0[YQhcW5iSFXLNlk{KGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHP5eI9{d2yrYzDOVW8yKGyndnXsd{BifCB{MECgeI8hOTByMDDuUUBi\nSncjC0PEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ NUDodFE1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5PVQzQDZpPkK4PVk1Ojh4PD;hQi=>
A549/TR NUfxO2VrSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MWi3NkBpenN? M3jqT2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PU9VWiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUGuO|A{|ryP MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTVyMUm0O{c,Ojl3MEG5OFc9N2F-
A549 NIL2NmhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M{nGd|czKGi{cx?= M3XsTmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTJwMEe0{txO M2fjVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUCxPVQ4Lz5{OUWwNVk1PzxxYU6=
A549/TR MVHGeY5kfGmxbjDhd5NigQ>? NUPYUI5EOi52IITvJFkvPiC3TR?= NICxXXozPCCqcoO= M2DRWWlv\HWldHnvckBw\iCUT2Og[4Vv\XKjdHnvckBqdiCqdX3hckBCPTR7L2TSJINmdGy|IHH0JFIvPCC2bzC5MlYhfU1iYX\0[ZIhOjRiaILzJIJ6KESFRlitSGEh\HmnLXLhd4VlKG[ub4egZ5l1d22ndILpZ{BidmGueYPpdy=> NIS4T289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWwNVk1Pyd-Mkm1NFE6PDd:L3G+
A549/TR MnTsSpVv[3Srb36gZZN{[Xl? M1Hmc|QvQCC3TR?= NViwNY04OjRiaILz MnPmSI94dnKnZ4XsZZRqd25ib3[gUI9vKGW6cILld5Nqd25iaX6gbJVu[W5iQUW0PU9VWiClZXzsd{BifCB2LkigeW0h[W[2ZYKgNlQhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTVyMUm0O{c,Ojl3MEG5OFc9N2F-
HCT116 NIfVZnBCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NUTuRYJ6PzJiaILz NFP0SWlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuNFAxOjYQvF2= M3yyUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNEK5PVU{Lz5|MESyPVk2OzxxYU6=
HT-29 NW\RPINJSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NHnUToM4OiCqcoO= NHzpdmxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUMVI6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;MD6yPO69VQ>? M2X5RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNEK5PVU{Lz5|MESyPVk2OzxxYU6=
HCT8 MmLsRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M4[2TFczKGi{cx?= M4jWVWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUPEBk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR|UxRTBwMkpOwG0> NGi5W5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MESyPVk2Oyd-M{C0Nlk6PTN:L3G+
HCT116 MmDQSpVv[3Srb36gZZN{[Xl? NFzHOFM5KGi{cx?= MW\Jcohq[mm2aX;uJI9nKEKvaUGgdJJwfGWrbjDlfJBz\XO|aX;uJIlvKGi3bXHuJGhEXDFzNjDj[YxteyCjZoTldkA5KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR{OUm1N{c,OzB2Mkm5OVM9N2F-
BEAS2B MWnGeY5kfGmxbjDhd5NigQ>? MX:0PEBpenN? NEHmRpBC[3SrdnH0bY9vKG:oIFvlZZAyN0O3bEOvUpJnOiCrbjDoeY1idiCERVHTNmIh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iTmHPNUBt\X[nbIOgcYVie3W{ZXSgZYZ1\XJiNEigbJJ{NCCHQ{WwQVAvODB6N{JOwG0> NUfQUHRKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C2NlY2PTVpPkOwOlI3PTV3PD;hQi=>
HepG2 MlS3R5l1d3SxeHnjbZR6KGG|c3H5 NV7RSoFiPDhiaILz NXHPbplRS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIlv[3WkYYTl[EBnd3JiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkK2{txO M2PBZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMEWxOFAyLz5|MUC1NVQxOTxxYU6=
MCF7 NE\KXHREgXSxdH;4bYNqfHliYYPzZZk> MkS3OFghcHK| MV\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4{Pc7:TR?= Ml\zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFyNUG0NFEoRjNzMEWxOFAyRC:jPh?=
A549 Mof4R5l1d3SxeHnjbZR6KGG|c3H5 NUfhZYg3PDhiaILz M3i2V2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHnuZ5Vj[XSnZDDmc5IhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjN4zszN M3jsXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMEWxOFAyLz5|MUC1NVQxOTxxYU6=
A549 MkL4RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NVTBTFRTPDhiaILz M4rabWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIlv[3WkYYTl[EBnd3JiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkWy{txO MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTd{NUK4PEc,OzF5MkWyPFg9N2F-
HepG2 MoLlRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MV60PEBpenN? M373ZmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXwS|Ih[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBqdmO3YnH0[YQh\m:{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD61Nu69VQ>? NH31N4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUeyOVI5QCd-M{G3NlUzQDh:L3G+
HOS NWPrUoFySW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M3nrdlQ5KGi{cx?= MYnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiRUzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHnuZ5Vj[XSnZDDmc5IhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjZ4zszN MkXlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF5MkWyPFgoRjNzN{K1Nlg5RC:jPh?=
MCF7 M2r4fWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NYi2bldCPDhiaILz MmDpRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPQ1[3JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBoem:5dHigbY5kfWKjdHXkJIZweiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwOEZOwG0> MnziQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF5MkWyPFgoRjNzN{K1Nlg5RC:jPh?=
HEK293FT MlnDSpVv[3Srb36gZZN{[Xl? MU[yOEBpenN? M1jXV2lvcGmkaYTpc44hd2ZibX;1d4UhT0:DVDDlfJBz\XO|ZXSgbY4hUEWNMkmzSnQh[2WubIOgZ48u\XiycnXzd4lv\yCycnWtdJJw\2i{ZXzpckBie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6g[4hz\WyrbjDvZ5Ridm:7bHH0bY9vKGmwY4XiZZRm\CCob4KgNlQhcHK|IHL5JGVNUVODLDDJR|UxRTBwMEO1{txO MmfzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVc3OjZ{MT:nQmNpTU2ETEyvZV4>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-IκBα / IκBα ; 

PubMed: 25897966     


HeLa cells were pre-treated with RTA 408 or bardoxolone methyl for 6 hours at the indicated concentrations followed by a five-minute treatment with TNFα. Protein levels of phospho-IκBα and total IκBα were evaluated by western blot. Actin was used as loading control. Data are representative of four experiments.

Bcl-xl / Bcl-2 / Bax / Cleaved caspase / Cytochrome C / PARP / Cleaved PARP ; 

PubMed: 25733817     


Representative blots of respective proteins measured to show the effect of CDDO-Me treatment on the expression levels of Bcl-xl, Bcl-2, Bax, PUMA, cytochrome c, cleaved caspase-3 (active), cleaved caspase-9 (active), PARP, and cleaved PARP in Ec109 and KYSE70 cells determined using Western blotting analysis. 

p-PI3K / PI3K / p-AMPK / AMPK / p-p38 MAPK / p38 MAPK / p-AKT / AKT / p-mTOR / mTOR; 

PubMed: 25733817     


Effects of CDDO-Me treatment on the expression levels of p-PI3K at Tyr458, PI3K, p-AMPK at Thr172, AMPK, p-p38 at Thr180, p38, p-Akt at Ser473, Akt, p-mTOR at Ser2448, mTOR, PTEN, beclin 1, LC3-I, and LC3-II in Ec109 and KYSE70 cells. Cellular lysates were analyzed by immunoblotting with respective first antibody followed by the second antibody. 

PTEN / PP2A / PHLPP1 ; 

PubMed: 22177954     


LNCaP and PC-3 cells were treated with CDDO-Me (0.3-5 µM) for 20 h and cell lysates were analyzed for PTEN, PP2A and PHLPP1 by immunoblotting. 

25897966 25733817 22177954
Immunofluorescence
PDI / SDHA ; 

PubMed: 26053096     


MDA-MB 435 cells were treated with or without 1.5 μM CDDO-Me for indicated time points. Immunocytochemistry using anti-PDI (red) and anti-SDHA (green) antibodies was performed and the representative fluorescence and phase contrast microscopic images of cells are shown. Scale bar: 20 μm.

c-PARP / Cytochrome C / COX IV; 

PubMed: 26053096     


E, F. MDA-MB 435 cells were untreated or treated with 1.5 μM CDDO-Me for 24 h. Immunocytochemistry of the cleaved PARP and staining with DAPI were performed (E). Immunocytochemistry of the cytochrome c (Cyt.c) and the subunit I of cytochrome c oxidase (COX IV) was performed (F) Representative fluorescence microscopic images of cells are shown. Scale bars: 50 μm.

26053096
Growth inhibition assay
Cell viability ; 

PubMed: 25733817     


(A) The chemical structure of CDDO-Me and (B) effects of CDDO-Me on the proliferation of Ec109, KYSE70, and Het-1A cells determined by the MTT assay. Notes: Cells were treated with CDDO-Me at 0.01, 0.05, 0.25, 1.0, and 5.0 μM for 24 or 48 hours. Data are the mean ± SD of at least four independent experiments.

25733817
In vivo

Bardoxolone Methyl (60 mg/kg) reduces the number, size, and severity of lung tumors in vivo. [4] Bardoxolone Methyl significantly reduces the in vivo inflammatory cytokine response following LPS challenge, induces HO-1 protein expression in the spleen, and protects mice against lethal-dose LPS. [5]

Protocol

Kinase Assay:

[3]

- Collapse

IKK assay :

To determine the effect of CDDO-Me on TNF-induced IKK activation, IKK is analyzed. Briefly, the IKK complex from whole-cell extracts was precipitated with antibody against IKKα and IKKβ and then treated with protein A/G-Sepharose beads. After 2 hours, the beads are washed with lysis buffer and then resuspended in a kinase assay mixture containing 50 mmol/L HEPES (pH 7.4), 20 mmol/L MgCl2, 2 mmol/L DTT, 20 μCi [γ-32P]ATP, 10 μmol/L unlabeled ATP, and 2 μg of substrate glutathione S-transferase-IκBα (amino acids 1-54). After incubation at 30°C for 30 minutes, the reaction is terminated by boiling with SDS sample buffer for 5 minutes. Finally, the protein is resolved on 10% SDS-PAGE, the gel is dried, and the radioactive bands are visualized with a Storm820. To determine the total amounts of IKK-α and IKK-β in each sample, 50 μg of whole-cell proteins are resolved on 7.5% SDS-PAGE, electrotransferred to a nitrocellulose membrane, and then blotted with either anti-IKK-α or anti-IKK-β antibody.
Cell Research:

[2]

- Collapse
  • Cell lines: HL-60, KG-1, and NB4 cells
  • Concentrations: ~5 μM
  • Incubation Time: 72 hours
  • Method:

    Leukemic cell lines are cultured at a density of 3.0 × 105 cells/mL, and AML mononuclear cells are cultured at 5 × 105 cells/mL in the presence or absence of indicated concentrations of CDDO-Me. Appropriate amounts of DMSO (final concentration less than 0.05%) are included as control. For cytotoxicity studies, 1 μM ara-C is added to the cultures. After 24 to 72 hours, viable cells are counted with the trypan blue dye exclusion method using a hematocytometer.


    (Only for Reference)
Animal Research:

[4]

- Collapse
  • Animal Models: Female A/J mice are injected i.p. with vinyl carbamate.
  • Dosages: ~60 mg/kg
  • Administration: Oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 21 mg/mL (41.52 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4%DMSO+30% PEG300+5% Tween+61%ddH2O
For best results, use promptly after mixing.
2.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 505.69
Formula

C32H43NO4

CAS No. 218600-53-4
Storage powder
in solvent
Synonyms RTA 402, TP-155, NSC 713200, CDDO Methyl Ester, CDDO-Me
Smiles CC1(CCC2(CCC3(C(C2C1)C(=O)C=C4C3(CCC5C4(C=C(C(=O)C5(C)C)C#N)C)C)C)C(=O)OC)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02316821 Completed Drug: RTA 402|Drug: Placebo Chronic Kidney Disease|Type 2 Diabetes Kyowa Kirin Co. Ltd. December 2014 Phase 2
NCT02036970 Completed Drug: Bardoxolone methyl|Drug: Placebo Pulmonary Arterial Hypertension|Pulmonary Hypertension|Interstitial Lung Disease|Idiopathic Interstitial Pneumonia|Idiopathic Pulmonary Fibrosis|Sarcoidosis|Respiratory Bronchiolitis Associated Interstitial Lung Disease|Desquamative Interstitial Pneumonia|Cryptogenic Organizing Pneumonia|Acute Interstitial Pneumonitis|Idiopathic Lymphoid Interstitial Pneumonia|Idiopathic Pleuroparenchymal Fibroelastosis Reata Pharmaceuticals Inc. May 2014 Phase 2
NCT01598363 Completed Drug: Digoxin|Drug: Rosuvastatin Healthy Volunteers Reata Pharmaceuticals Inc. June 2012 Phase 1
NCT01551446 Withdrawn Drug: Bardoxolone Methyl Renal Insufficiency Chronic|Diabetes Mellitus Type 2 Reata Pharmaceuticals Inc. April 2012 Phase 1
NCT01503866 Completed Drug: bardoxolone methyl Healthy Reata Pharmaceuticals Inc. December 2011 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

IκB/IKK Signaling Pathway Map

Related IκB/IKK Products

Tags: buy Bardoxolone Methyl | Bardoxolone Methyl supplier | purchase Bardoxolone Methyl | Bardoxolone Methyl cost | Bardoxolone Methyl manufacturer | order Bardoxolone Methyl | Bardoxolone Methyl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID